Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088608 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00088608 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT00088608, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
Interventions
- DRUG SOM230 s.c.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088608
The ClinicalTrials.gov registry entry for NCT00088608 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SOM230 s.c. is the first listed.
NCT00088608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088608 about?
NCT00088608 is a clinical study titled "A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease". The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
What is the current status of trial NCT00088608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00088608?
The interventions under investigation include: SOM230 s.c. (DRUG).
Who is sponsoring clinical trial NCT00088608?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.